Researchers launched a unique collaboration on Wednesday aimed at getting cancer drugs to the market more quickly in which three companies will cooperate with the U.S. government and non-profit groups to test five experimental breast cancer drugs.
The five-year, $26 million study called Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis, or I-SPY2, will aim to use DNA to match the best drug to each patient and to more quickly toss out approaches that do not work or are too toxic.
"They'll get the latest and greatest in terms of targeted drugs," Dr. Anna Barker, deputy director of the National Cancer Institute, said in an interview.
"I think it's the future. Government couldn't have done it on their own and these companies couldn't have done it on their own."
Unusually, the companies agreed to share information on using genes to predict how well a patient will respond as part of the Biomarkers Consortium, which includes the U.S. Food and Drug Administration and the National Institutes of Health.
"I-SPY 2 will provide a path to personalized medicine," said Dr. Laura Esserman, a breast cancer surgeon at the University of California San Francisco who will help lead the clinical trials. "We intend that every drug will graduate with a companion marker."
The trial will match patients to one of five experimental drugs:
-- ABT-888 or veliparib, being developed by Abbott Laboratories. The pill is a PARP inhibitor, which blocks a cell repair enzyme used by cancer cells.
-- AMG 655 or conatumumab, a targeted drug being developed by Amgen. It boosts a protein called APO/TRAIL that causes cancer cells to self-destruct.
-- Amgen's AMG 386, an angiogenesis inhibitor that stops tumors from growing blood vessels to nourish themselves.
-- CP-751,871 or figitumumab, being developed by Pfizer Inc to target the insulin growth factor receptor or IGFR.
-- Pfizer's HKI-272 or neratinib, another targeted therapy called a Pan ErbB inhibitor that targets several related receptors used by cancer cells.
The group is negotiating with other companies to add their experimental drugs to the mix.
"It'll speed up the whole process," Barker said.
The drug company lobby group PhRMA estimates it can take as long as 15 years and cost more than $1.3 billion dollars to take a new drug from laboratory to pharmacy.
Patients at 20 cancer centers will be tested right after they get tiny samples of tissue taken in biopsies. Before they ever get surgery, they will be treated with one of the drugs to see if this helps prevent tumor spread.
Up to 12 different cancer drugs will be tested. Unusually, the group has FDA approval to drop and add drugs throughout the course of the trial without having to stop it to write a whole new protocol.
Countries should set a target of reaching $40 to $80 per tonne of CO2 by 2020, and of $50 to $100 per tonne by 2030, they said.
Indian government issues guidelines to deal with Zika virus
Number just 1 million shy of those who would have been without coverage under previous Republican draft
The human genome has some 25,000 genes composed of more than three billion pairing of building-block molecules.
On a pro-forma 2016 basis, the merged group would have combined sales of approximately $13.2 billion (11.8 billion euros) and underlying or operating profit of $2.3 billion.
The seed vault that protects the worlds' seed crops, also protects European and South American varieties of aubergine, lettuce, barley and potatoes.
Early polls indicated broad support for the plan, but the most recent survey, published on May 10, showed the "yes" side slipping to 56 percent -- a drop of five points from late March.
Authorities declare quarantine against movement of chicken and ducks
Cholera cases in country could reach 300,000 within six months, WHO Yemen representative says
In recent years rangers have tried to clean up Khao Sam Roi Yot national park and this year were rewarded with a sea of pink flowers.
Over 17,200 suspected cases of cholera were reported in Yemen
Cholera has hit 13 of 18 Somalia’s provinces, in biggest outbreak in the country in 5 years, according to WHO
The fate of the superhighway remains on hold pending the final decision of the Abuja authorities, expected in the coming weeks.
The new policy would also help guarantee the labor and human rights of the six million small farmers and 30 million workers who harvest rubber in countries such as Indonesia, Thailand and Brazil.
Turkey makes strides in developing its medical tourism sector by implementing policies that facilitate foreign visitors
A prolonged drought descended on the region last year, shriveling two rivers that feed into Lake Atescatempa, and with it the flow of tourists to the area and the livelihood of residents.